TECH earnings analysis
What we found in TECH's 10-K: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Bio-Techne delivered a sharp reported earnings recovery in fiscal 2026, but revenue was essentially flat at $1.215 billion and adjusted earnings declined 1% as product mix and pricing pressures offset growth. Protein Sciences remains the principal earnings engine, while Diagnostics and Spatial Biology generated 4% organic growth but reported revenue declined because of the held-for-sale business and Exosome Diagnostics divestiture. The Merck agreement provides a defined $73.00-per-share cash consideration, but approval and closing conditions, the approximately $1.0 billion Wilson Wolf obligation, and ongoing margin pressure keep the overall outlook neutral.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Broad life-science portfolio and positioning
- Bio-Techne describes a strategy built around a deep product portfolio and application expertise, selling reagents, instruments and services used in life-science research, diagnostics, drug discovery, and cell and gene therapy. Protein Sciences is described as a leading developer and manufacturer of biological reagents, while Diagnostics and Spatial Biology includes automated spatial-biology and molecular-diagnostics solutions.
- Reported profitability rebounded
- Operating performance rebounded sharply after fiscal 2025 exceptional charges: operating income rose to $251.9 million from $102.3 million, and diluted EPS increased to $1.16 from $0.46. The filing attributes much of the earnings increase to the absence of the prior year's impairment and arbitration award.
- Strong operating cash generation
- Cash generation remained solid, with operating cash flow of $292.1 million in fiscal 2026 versus $287.6 million in fiscal 2025 and $299.0 million in fiscal 2024. Capital additions declined to $28.9 million from $31.0 million and $62.9 million, respectively.
- Protein Sciences drives earnings
- Protein Sciences remains the core business at $874.6 million of revenue and $359.4 million of segment operating income, versus $336.4 million of revenue and $37.7 million of segment operating income for Diagnostics and Spatial Biology.
- Merck transaction provides cash exit
- The company entered into a merger agreement with Merck KGaA on June 25, 2026, under which shareholders would receive $73.00 in cash per share. The transaction is expected to close by late 2026 or early 2027, subject to shareholder, antitrust and investment-screening approvals.
- Debt reduction and shareholder returns
- Capital allocation included $49.9 million of dividends and $41.7 million of share repurchases in fiscal 2026. Debt repayments of $146.0 million reduced borrowings under the revolving facility to $200.0 million, leaving $800.0 million of available capacity.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Merger approval and closing risk
- The pending Merck transaction is subject to approval by holders of a majority of voting power, required antitrust and investment-screening approvals, and the absence of an injunction or burdensome condition. The company could owe Merck a termination fee of approximately $230.5 million in specified circumstances, while Merck could owe Bio-Techne approximately $576.1 million in certain regulatory-failure scenarios.
- Large Wilson Wolf funding obligation
- Bio-Techne is obligated to acquire the remaining 80.1% of Wilson Wolf on December 31, 2027 after the first forward-contract milestone was triggered. The second option payment is forecast at approximately $1.0 billion plus potential contingent consideration, creating a substantial future funding requirement.
- Mix and pricing pressure persist
- Underlying profitability weakened despite the reported earnings rebound: adjusted net earnings decreased 1% to $303.3 million in fiscal 2026, and adjusted gross margin fell to 69.6% from 70.4% due primarily to unfavorable product mix and pricing pressures. Reported segment gross margins also declined to 75.0% in Protein Sciences and 55.2% in Diagnostics and Spatial Biology.
- Meaningful foreign-exchange exposure
- Approximately 33% of fiscal 2026 consolidated sales were in foreign currencies, including 17% in euros and 5% in Chinese yuan. A hypothetical 10% appreciation of the U.S. dollar against the principal currencies would reduce translated foreign-subsidiary earnings by $1.2 million and create additional transaction losses of $4.5 million.
- Restructuring execution and costs
- The company began additional restructuring early in the fourth quarter to streamline brand architecture and realign functions, and expects to incur related costs through fiscal 2027. Fiscal 2026 restructuring and restructuring-related costs totaled $4.2 million for these new actions, in addition to $8.9 million from prior actions.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $1.16
- Gross margin
- 65.8%
- Operating margin
- 20.7%
- Segment
- Protein Sciences: $874.6 million, up 1% reported; organic revenue decreased 1%, while foreign currency contributed 2%
- Segment
- Diagnostics and Spatial Biology: $336.4 million, down 3% reported; organic growth was 4%, offset by an 8% unfavorable impact from the held-for-sale business
- Segment
- Other revenue: $5.4 million; intersegment revenue: $(1.4) million
What they said about what is next.
The 10-K provides no quantitative fiscal 2027 revenue or EPS guidance; annual outlook was deferred to the earnings press release or call.
The filing reads about the same as the one before it.
What came before.
- 10-Q · May 6, 2026
- Bio-Techne Corporation (TECH) reported Q3 FY2026 results characterized by a revenue miss and modest EPS beat. Revenue was $311.4 million, reflecting a 2% decline year-over-year, while diluted EPS was $0.53, exceeding…
- 10-Q · February 4, 2026
- Bio-Techne Corporation reported flat net sales of $295.9 million for Q2 2026, slightly beating revenue expectations by 1.6%. The company delivered adjusted EPS of $0.46, surpassing estimates by 15%. Notable segment…
- 10-Q · November 5, 2025
- Bio-Techne's Q1 2026 report shows a 1% decline in revenue from the prior year, reflecting challenges in its Protein Sciences segment. However, gross margin improved to 65.6%, contributing to an adjusted EPS of $0.42,…
- 10-K · August 22, 2025
- Bio-Techne Corporation's FY2025 10-K report reveals a strategic focus on innovation and acquisition, particularly with the acquisition of Lunaphore, driving overall revenue growth of 5% to $1.22 billion. However, the…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing TECH makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever